2007 F2 CONFERENCE LOGIN HERE

 

 
: :   
 
Partners
William F. Westerman
Ken-Ichi Hattori
Scott M. Daniels
Stephen G. Adrian
John P. Kong
Sadao Kinashi
Thomas E. Brown
Lee C. Wright
Michael J. Caridi
Shuji Yoshizaki
Darrin A. Auito*
 
Of Counsel
Nicolas E. Seckel
Yasuhisa Kurose**
Stephen B. Parker
 
Associates
Kenneth H. Salen*
William M. Schertler*
Ryan B. Chirnomas
Andrew G. Melick*
Kumiko Ide
Dennis M. Hubbs*
Robert Y. Raheja
Bernadette K. McGann*
 
Technical Advisors

Michinori Irikawa**

 
Japanese Benrishi
Ken-Ichi Hattori
Sadao Kinashi
Shuji Yoshizaki
Yasuhisa Kurose**
Tsuyoshi Nakamura
Yoshiya Nakamura

 

*Practice limited to matters and proceedings before federal courts and agencies.

**Not admitted to practice law in the U.S.

 







Ryan B. Chirnomas

Email: rchirnomas@whda.com
Add to my contacts

B.S. Molecular and Cellular Biology (University of Arizona, 2000); cum laude

J.D. (American University, Washington College of Law, 2005)

Admitted to practice before the U.S. Patent and Trademark Office, 2005

Admitted to bar (Virginia, 2005 and District of Columbia, 2007)

Prior Affiliation:
Dr. Volker Vossius Patentanwaltskanzlei/Rechtsandwaltskanzlei, Munich, Germany

Laboratory of Mammary Gland Biology, University of Arizona

Co-Author:
Brief of amicus curiae on behalf of Public Knowledge in Knorr-Bremse v. Dana Corp., filed with the Federal Circuit Court of Appeals.

"Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: Requirements for metabolism of benzo[a]pyrene to 7r,8t-dihydroxy-9t, 10-epoxy-7,8,9,20-tetrahydrobenzo[a]pyrene." Cancer Research, 2002

"Epigenetics of breast cancer: Polycyclic aromatic hydrocarbons as risk factors." Environmental and Molecular Mutagenesis, 2002.

"Deoxycholate, an endogenous tumor promoter and DNA damaging agent, modulates BRCA-1 expression in apoptosis-sensitive epithelial cells: Loss of BRCA-1 Expression in colonic adenocarcinomas." Nutrition and Cancer, 2003.

Representative Technologies and Specialties:
Biological arts, in particular, gene therapy and other therapeutic methods, medical devices, cancer biology, microscopy, microarray/biochip assay systems, transgenic animals, screening methods, diagnostic methods, and artificial bone technologies; mechanical arts, in particular, general automotive technologies, hybrid vehicle systems, vibration isolation, and clean room equipment; internet and business method technologies.